Print PDF

Sheppard Mullin Advises ArchiMed in Three Acquisitions


Sheppard Mullin represented ArchiMed, a European healthcare-focused private equity fund, in three simultaneous acquisitions that will create an innovative market leader in the bioanalytical market:

  • The acquisition of ImaBiotech, a French-based provider specializing in molecular imaging services and products aiming at enhancing the development of new drugs through innovative proprietary technologies
  • The acquisition of Pyxant Labs, a Colorado Springs research lab that specializes in biological testing for the pharmaceutical industry
  • As part of the deal with ArchiMed, Pyxant acquired a Salt Lake City-based bioanalytical and oligonucleotide studies business, creating the nation’s largest independent specialty lab operation focused on testing samples from clinical trial subjects to ensure the safety and effectiveness of new drugs under development

The Sheppard Mullin deal team was led by New York partner Valérie Demont and New York associate Karl Buhler.  Special assistance was provided by partners Greg Berk, Dmitriy Chelnitsky, Judy Fiorini, Allison Fulton, Justin Hepworth, Matt Shatzkes, and Dan Yannuzzi, associates Sarah Ben-Moussa, Brian Egan, Trevor Quist, and Lindsay Stone, and attorney Christina Nguyen.

Jump to Page

By scrolling this page, clicking a link or continuing to browse our website, you consent to our use of cookies as described in our Cookie and Advertising Policy. If you do not wish to accept cookies from our website, or would like to stop cookies being stored on your device in the future, you can find out more and adjust your preferences here.